Key result
SARS-CoV-2 infection causes severe cardiovascular complications, with no therapies showing proven efficacy in high-risk patients.
Answers are grounded in this paper and cite their sources.
The outbreak of coronavirus disease 2019 (COVID-19), an infectious disease with severe acute respiratory syndrome, has now become a worldwide pandemic. Despite the respiratory complication, COVID-19 is also associated with significant multiple organ dysfunction, including severe cardiac impairment. Emerging evidence reveals a direct interplay between COVID-19 and dire cardiovascular complications, including myocardial injury, heart failure, heart attack, myocarditis, arrhythmias as well as blood clots, which are accompanied with elevated risk and adverse outcome among infected patients, even sudden death. The proposed pathophysiological mechanisms of myocardial impairment include invasion of SARS-CoV-2 virus via angiotensin-converting enzyme 2 to cardiovascular cells/tissue, which leads to endothelial inflammation and dysfunction, de-stabilization of vulnerable atherosclerotic plaques, stent thrombosis, cardiac stress due to diminish oxygen supply and cardiac muscle damage, and myocardial infarction. Several promising therapeutics are under investigation to the overall prognosis of COVID-19 patients with high risk of cardiovascular impairment, nevertheless to date, none have shown proven clinical efficacy. In this comprehensive review, we aimed to highlight the current integrated therapeutic approaches for COVID-19 and we summarized the potential therapeutic options, currently under clinical trials, with their mechanisms of action and associated adverse cardiac events in highly infectious COVID-19 patients.
No takes yet. Share an insight, caveat, or question.
Samidurai et al. (2020) conducted a review in COVID-19 and associated cardiovascular complications. Potential COVID-19 therapeutic options was evaluated. SARS-CoV-2 infection via ACE2 causes severe cardiovascular complications, and no investigated therapeutics have yet shown proven clinical efficacy in high-risk COVID-19 patients.
Synapse has enriched 10 related papers. Consider them for comparative context: